कृपया अन्य खोज का प्रयास करें
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Nello Mainolfi | 43 | 2017 | Co-Founder, President, CEO & Director |
Elena H. Ridloff | 42 | 2021 | Independent Director |
Jeffrey W. Albers | 51 | 2020 | Independent Director |
Gorjan Hrustanovic | 35 | 2020 | Independent Director |
Joanna Caroline Horobin | 69 | 2018 | Independent Director |
John M. Maraganore | 62 | 2022 | Independent Director |
Pamela Esposito | 49 | 2020 | Independent Director |
Felix James Baker | 55 | 2024 | Lead Independent Director |
Bruce L. Booth | 50 | 2015 | Co-Founder & Independent Chairman |
Leigh Morgan | 55 | 2022 | Independent Indepednet Director |
Victor Sandor | 58 | 2022 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है